Literature DB >> 21368287

Evidence of canonical somatic hypermutation in hairy cell leukemia.

Evgeny Arons1, Laura Roth, Jeffrey Sapolsky, Tara Suntum, Maryalice Stetler-Stevenson, Robert J Kreitman.   

Abstract

To compare hairy cell leukemia (HCL) with chronic lymphocytic leukemia (CLL) and normal B cells with respect to their B-cell receptors, somatic hypermutation (SHM) features in HCL were examined in a series of 130 immunoglobulin gene heavy chain rearrangements, including 102 from 100 classic (HCLc) and 28 from 26 variant (HCLv) patients. The frequency of unmutated rearrangements in HCLc was much lower than that in HCLv (17% vs 54%, P < .001) or historically in CLL (17% vs 46%, P < .001), but HCLv and CLL were similar (P = .45). As previously reported for CLL, evidence of canonical SHM was observed in HCLc rearrangements, including: (1) a higher ratio of replacement to silent mutations in the complementarity determining regions than in the framework regions (2.83 vs 1.41, P < .001), (2) higher transition to transversion ratio than would be expected if mutations were random (1.49 vs 0.5, P < .001), and (3) higher than expected concentration of mutations within RGYW hot spots (13.92% vs 3.33%, P < .001). HCLv met these 3 criteria of canonical SHM to a lesser extent. These data suggest that, whereas HCLc cells may recognize antigen-like CLL and normal B cells before malignant transformation, HCLv cells from some patients may originate differently, possibly without undergoing antigen recognition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368287      PMCID: PMC3100693          DOI: 10.1182/blood-2010-11-316737

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  The inference of antigen selection on Ig genes.

Authors:  I S Lossos; R Tibshirani; B Narasimhan; R Levy
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

2.  Transcription-dependent somatic hypermutation occurs at similar levels on functional and nonfunctional rearranged IgH alleles.

Authors:  Laurent Delpy; Christophe Sirac; Caroline Le Morvan; Michel Cogné
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

Review 3.  V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin.

Authors:  V Vanhentenrijk; A Tierens; I Wlodarska; G Verhoef; C D Wolf-Peeters
Journal:  Leukemia       Date:  2004-10       Impact factor: 11.528

4.  Evolution of autoantibody responses via somatic hypermutation outside of germinal centers.

Authors:  Jacqueline William; Chad Euler; Sean Christensen; Mark J Shlomchik
Journal:  Science       Date:  2002-09-20       Impact factor: 47.728

5.  Evidence for involvement of a hydrophobic patch in framework region 1 of human V4-34-encoded Igs in recognition of the red blood cell I antigen.

Authors:  Kathleen N Potter; Paul Hobby; Susanne Klijn; Freda K Stevenson; Brian J Sutton
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

6.  CD40-CD40L independent Ig gene hypermutation suggests a second B cell diversification pathway in humans.

Authors:  S Weller; A Faili; C Garcia; M C Braun; F Le Deist F; G de Saint Basile G; O Hermine; A Fischer; C A Reynaud; J C Weill
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

7.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

Authors:  R J Kreitman; W H Wilson; K Bergeron; M Raggio; M Stetler-Stevenson; D J FitzGerald; I Pastan
Journal:  N Engl J Med       Date:  2001-07-26       Impact factor: 91.245

Review 8.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

Authors:  J J M van Dongen; A W Langerak; M Brüggemann; P A S Evans; M Hummel; F L Lavender; E Delabesse; F Davi; E Schuuring; R García-Sanz; J H J M van Krieken; J Droese; D González; C Bastard; H E White; M Spaargaren; M González; A Parreira; J L Smith; G J Morgan; M Kneba; E A Macintyre
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

9.  Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins.

Authors:  George F Widhopf; Laura Z Rassenti; Traci L Toy; John G Gribben; William G Wierda; Thomas J Kipps
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

10.  The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process.

Authors:  Bradley T Messmer; Emilia Albesiano; Davorka Messmer; Nicholas Chiorazzi
Journal:  Blood       Date:  2003-12-24       Impact factor: 22.113

View more
  13 in total

1.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Authors:  Liqiang Xi; Evgeny Arons; Winnifred Navarro; Katherine R Calvo; Maryalice Stetler-Stevenson; Mark Raffeld; Robert J Kreitman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

Review 2.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

Review 3.  Immunoconjugates and new molecular targets in hairy cell leukemia.

Authors:  Robert J Kreitman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

4.  Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.

Authors:  Farhad Ravandi; Susan O'Brien; Jeffrey Jorgensen; Sherry Pierce; Stefan Faderl; Alessandra Ferrajoli; Charles Koller; Pramoda Challagundla; Sergernne York; Mark Brandt; Rajyalakshmi Luthra; Jan Burger; Deborah Thomas; Michael Keating; Hagop Kantarjian
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

5.  Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Authors:  Michael R Grever; Omar Abdel-Wahab; Leslie A Andritsos; Versha Banerji; Jacqueline Barrientos; James S Blachly; Timothy G Call; Daniel Catovsky; Claire Dearden; Judit Demeter; Monica Else; Francesco Forconi; Alessandro Gozzetti; Anthony D Ho; James B Johnston; Jeffrey Jones; Gunnar Juliusson; Eric Kraut; Robert J Kreitman; Loree Larratt; Francesco Lauria; Gerard Lozanski; Emili Montserrat; Sameer A Parikh; Jae H Park; Aaron Polliack; Graeme R Quest; Kanti R Rai; Farhad Ravandi; Tadeusz Robak; Alan Saven; John F Seymour; Tamar Tadmor; Martin S Tallman; Constantine Tam; Enrico Tiacci; Xavier Troussard; Clive S Zent; Thorsten Zenz; Pier Luigi Zinzani; Brunangelo Falini
Journal:  Blood       Date:  2016-11-30       Impact factor: 22.113

6.  Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

Authors:  David Sanchez-Martin; Thomas S Uldrick; Hyeongil Kwak; Hidetaka Ohnuki; Mark N Polizzotto; Christina M Annunziata; Mark Raffeld; Kathleen M Wyvill; Karen Aleman; Victoria Wang; Vickie A Marshall; Denise Whitby; Robert Yarchoan; Giovanna Tosato
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

7.  Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome.

Authors:  Evgeny Arons; Sharon Adams; David J Venzon; Ira Pastan; Robert J Kreitman
Journal:  Br J Haematol       Date:  2014-06-13       Impact factor: 6.998

8.  Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.

Authors:  Nabila Belhouachi; Aliki Xochelli; Myriam Boudjoghra; Claude Lesty; Nathalie Cassoux; Christine Fardeau; Thi Ha Chau Tran; Sylvain Choquet; Bishnu Sarker; Caroline Houillier; Agusti Alentorn; Phuc LeHoang; Carole Soussain; Valerie Touitou; Helene Merle-Beral; Khe Hoang-Xuan; Bahram Bodaghi; Kostas Stamatopoulos; Frederic Davi
Journal:  Blood Adv       Date:  2020-04-14

Review 9.  B-cell receptor signaling as a driver of lymphoma development and evolution.

Authors:  Carsten U Niemann; Adrian Wiestner
Journal:  Semin Cancer Biol       Date:  2013-09-20       Impact factor: 15.707

10.  Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia.

Authors:  Robert J Kreitman; Wyndham Wilson; Katherine R Calvo; Evgeny Arons; Laura Roth; Jeffrey Sapolsky; Hong Zhou; Mark Raffeld; Maryalice Stetler-Stevenson
Journal:  Clin Cancer Res       Date:  2013-11-25       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.